Drug Profile
P 4055
Alternative Names: elaidic acid cytarabinLatest Information Update: 21 Jun 2001
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 21 Jun 2001 No-Development-Reported for Cancer in Norway (Unknown route)
- 07 Dec 1998 New profile
- 07 Dec 1998 Preclinical development for Cancer in Norway (Unknown route)